Article
Effect of vasopressin and methylprednisolone versus placebo on return of spontaneous circulation in patients with in-hospital cardiac arrest
Publish date: January 7, 2022
Dr. Miller Clinical question: Does the administration of vasopressin and...
READ MORE >News
Dapagliflozin trial in CKD halted because of high efficacy
Publish date: March 30, 2020
An independent data monitoring committee recommended stopping the trial.
READ MORE >News
New ASAM guideline released amid COVID-19 concerns
Publish date: March 20, 2020
During the COVID-19 pandemic, “it is especially important” for clinicians to ensure that individuals with OUD continue to receive evidence-based care, said Dr. Paul H. Earley.
READ MORE >News
Pathways to new therapeutic agents for human coronaviruses
Publish date: February 13, 2020
Researchers have been identifying old and new therapeutics to target metabolic pathways and modes of infection for human coronaviruses.
READ MORE >News
What 2019’s top five CAD trials tell us
Publish date: January 29, 2020
SNOWMASS, COLO. – Triple therapy as a triple threat – a three-pronged threat to patient safety, Dr. Malcolm R. Bell says.
READ MORE >News
Cardiac biomarkers refine antihypertensive drug initiation decisions
Publish date: January 22, 2020
PHILADELPHIA – Analysis showcases a better way to select patients for intensive BP lowering.
READ MORE >News
ENGAGE AF-TIMI: Insulin linked to greater risk for stroke, CV death, bleeding
Publish date: December 16, 2019
LOS ANGELES – Use of novel oral anticoagulants may be preferred over vitamin K antagonists in patients with diabetes and AFib.
READ MORE >News
New heart failure trial data presage guideline revisions
Publish date: December 9, 2019
PHILADELPHIA – Recent trial findings for sacubitril/valsartan and dapagliflozin in heart failure patients provide a blueprint for guideline changes.
READ MORE >News
Aspirin plus a DOAC may do more harm than good in some
Publish date: December 8, 2019
Adding aspirin to DOAC therapy for the secondary prevention of VTE or the prevention of stroke associated with NVAF without a clear indication increased bleeding risks in a large cohort.
READ MORE >News
DAPA-HF: Dapagliflozin benefits regardless of age, HF severity
Publish date: November 25, 2019
PHILADELPHIA – The SGLT2 inhibitor had similar efficacy in the elderly, and across the spectrum of baseline symptom status.
READ MORE >
